These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 25913507

  • 1. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
    Bethune GC, Veldhuijzen van Zanten D, MacIntosh RF, Rayson D, Younis T, Thompson K, Barnes PJ.
    Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS, Bowman AS, Zehir A, Razavi P, Brogi E, Ladanyi M, Arcila ME, Wen HY, Ross DS.
    Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N, Flanagan L, Harford J, Gannon JM, Quinn CM.
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [Abstract] [Full Text] [Related]

  • 10. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio <2.0 and Average HER2 Copy Number ≥4.0 and <6.0.
    Hoda RS, Brogi E, Xu J, Ventura K, Ross DS, Dang C, Robson M, Norton L, Morrow M, Wen HY.
    Arch Pathol Lab Med; 2020 May; 144(5):597-601. PubMed ID: 31647316
    [Abstract] [Full Text] [Related]

  • 11. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
    Guo L, Yuan P, Zhang J, Ling Y, Li W, Zhao B, Ying J, Xuan L.
    Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009
    [Abstract] [Full Text] [Related]

  • 12. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Liu ZH, Wang K, Lin DY, Xu J, Chen J, Long XY, Ge Y, Luo XL, Zhang KP, Liu YH, Xu FP.
    Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
    [Abstract] [Full Text] [Related]

  • 13. Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results.
    Wang B, Ding W, Sun K, Wang X, Xu L, Teng X.
    Sci Rep; 2019 Nov 13; 9(1):16726. PubMed ID: 31723206
    [Abstract] [Full Text] [Related]

  • 14. Impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) gene testing in invasive breast cancers: A single center study.
    Lim TH, Lim AST, Tien SL, Tan PH.
    Ann Diagn Pathol; 2022 Jun 13; 58():151935. PubMed ID: 35313158
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
    Bethune GC, Pettit AS, Veldhuijzen van Zanten D, Barnes PJ.
    Histopathology; 2017 May 13; 70(6):966-974. PubMed ID: 28032917
    [Abstract] [Full Text] [Related]

  • 17. Implementation of the 2018 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2/neu Assessment by FISH in breast cancers: predicted impact in a single institutional cohort.
    Zare S, Rong J, Daehne S, Roma A, Hasteh F, Dell'Aquila M, Fadare O.
    Mod Pathol; 2019 Nov 13; 32(11):1566-1573. PubMed ID: 31190000
    [Abstract] [Full Text] [Related]

  • 18. Assessing the impact of the 2018 American Society of Clinical Oncology/College of American Pathologists recommendations on human epidermal growth factor receptor 2 testing by fluorescence in situ hybridization in breast carcinoma.
    Murray C, Flanagan L, D'Arcy C, Gullo G, Quinn CM.
    Virchows Arch; 2020 Mar 13; 476(3):367-372. PubMed ID: 31375912
    [Abstract] [Full Text] [Related]

  • 19. Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines.
    Qian XL, Wen HY, Yang YL, Gu F, Guo XJ, Liu FF, Zhang L, Zhang XM, Fu L.
    Breast Cancer Res Treat; 2016 Aug 13; 159(1):31-9. PubMed ID: 27455837
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.